Medical and scientific advancements in research and clinical experience are leading to improved methodologies in the detection, diagnosis and treatment of bladder cancer. The eight (8) accredited activities provided in this educational offering are intended to provide useful information to the global community of clinicians who deal with bladder cancer in their patient populations.
Multimedia Activities
These multimedia activities provide a random-access learning experience by incorporating the use of slide/audio presentations augmented by fully referenced text. The presentations are then followed by faculty panel roundtable discussions. We hope you enjoy this engaging learning format.Activity One
Do variants in non-muscle-invasive Bladder Cancer (NMIBC) Matter?
Maximilian Burger, MD University of Regensburg Regensburg, Germany
Maximilian Burger, MD University of Regensburg Regensburg, Germany
Includes:
• Panel Introduction
• Faculty Presentation
• Panel Discussion
• Panel Introduction
• Faculty Presentation
• Panel Discussion
Activity Two
Understanding Biomarker Performance for Bladder Cancer Surveillance
Yair Lotan, MD
UT Southwestern Med. Ctr.
Dallas, TX
Yair Lotan, MD
UT Southwestern Med. Ctr.
Dallas, TX
Includes:
• Panel Introduction
• Faculty Presentation
• Panel Discussion
• Panel Introduction
• Faculty Presentation
• Panel Discussion
Activity Three
Understanding the Spectrum of Tumors after BCG Failure
Ashish Kamat, MD
University of Texas MD Anderson Cancer Ctr.
Houston, TX
Ashish Kamat, MD
University of Texas MD Anderson Cancer Ctr.
Houston, TX
Includes:
• Panel Introduction
• Faculty Presentation
• Panel Discussion
• Panel Introduction
• Faculty Presentation
• Panel Discussion
Activity Four
How to treat Bladder Cancer if BCG is unavailable
J.A. Fred Witjes, MD
Univ. Hospital Nijmegen
The Netherlands
J.A. Fred Witjes, MD
Univ. Hospital Nijmegen
The Netherlands
Includes:
• Panel Introduction
• Faculty Presentation
• Panel Discussion
• Panel Introduction
• Faculty Presentation
• Panel Discussion
Activity Five
What to do now that my patient’s tumor has been molecularly characterized
Arnulf Stenzl, MD
University of Tübingen Medical School
Tübingen, Germany
Arnulf Stenzl, MD
University of Tübingen Medical School
Tübingen, Germany
Includes:
• Panel Introduction
• Faculty Presentation
• Panel Discussion
• Panel Introduction
• Faculty Presentation
• Panel Discussion
Activity Six
T1 High Grade Bladder Cancer
Shahrokh F. Shariat, MD
Medical University of Vienna
Vienna, Austria
Shahrokh F. Shariat, MD
Medical University of Vienna
Vienna, Austria
Includes:
• Panel Introduction
• Faculty Presentation
• Panel Discussion
• Panel Introduction
• Faculty Presentation
• Panel Discussion
Activity Seven
Role of Neoadjuvant Chemotherapy in Bladder Cancer
H. Barton Grossman, MD
University of Texas MD Anderson Cancer Ctr. Houston, TX
H. Barton Grossman, MD
University of Texas MD Anderson Cancer Ctr. Houston, TX
Includes:
• Panel Introduction
• Faculty Presentation
• Panel Discussion
• Panel Introduction
• Faculty Presentation
• Panel Discussion
Activity Eight
Optimal Surveillance for Follow-up of NMIBC
James Catto, MD
University of Sheffield Sheffield, UK
James Catto, MD
University of Sheffield Sheffield, UK
Includes:
• Panel Introduction
• Faculty Presentation
• Panel Discussion
• Panel Introduction
• Faculty Presentation
• Panel Discussion